Phase 3 N=509 Pregabalin Versus Levetiracetam In Partial Seizures
Partial Seizures
Primary: Proportion of Participants With Response to Treatment — 0.59; 0.59 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=100 Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)
Anesthesia
Primary: Residual Neuromuscular Blockade Evidenced by T4/T1 Ratio at the Time of Tracheal Extubation — 1.02; 0.78 T4/T1 Ratio
Phase 3 N=15 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Gastric Cancer
Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months
Phase 3 N=49 Randomized Trial of Inhaled Nitric Oxide to Augment Tissue Perfusion in Sepsis
Sepsis
Primary: Change in the Sequential Organ Failure Assessment (SOFA) Score
Phase 3 N=326 Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
Pseudobulbar Affect (PBA)
Primary: PBA Episode Rate Ratio (Post/Pre), Regression Adjusted — 0.247; 0.237; 0.465 Unit-free (ratio of episodes/week) — p=<0.0001
Phase 3 N=20 Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)
Allergic Rhinitis
Primary: Change in Sneezing Symptom — 1; 1 sneezes
Phase 3 N=139 Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)
Dysmenorrhea
Primary: Total Pain Relief Score Over the First 6 Hours (TOPAR6) After the Initial Dose — 17.38; 16.49 Score on a Scale — p=0.043
Phase 3 N=218 A Confirmatory Study of Fentanyl in Participants With Osteoarthritis or Low Back Pain
Chronic Pain · Osteoarthritis · Low Back Pain
Primary: Time From the Initial Day of Application in Double-Blind Period to Withdrawal Because of Insufficient Analgesic Efficacy — NA; NA Days — p=0.0846
Phase 3 N=452 A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 92 or Early Withdrawal — 82.1; 84.4; -23.6; -26.9 Units on scale
Phase 3 N=328 A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment — -58.9; -58.7 Percentage Change
Phase 3 N=7,744 Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Meningitis · Meningococcal Infection
Primary: Percentages of Subjects With At Least One Severe Systemic Reaction After Any Vaccination — 16; 13 Percentages of subjects
Phase 3 N=2,031 HIV Testing & Womens Attitudes on HIV Vaccine Trials
HIV
Primary: Number of Participants Who Accepted Rapid HIV Testing. — 458; 401; 410; 418 participants — p=0.05
Phase 3 N=604 Efficacy of Nalmefene in Patients With Alcohol Dependence
Alcohol Dependence
Primary: Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs) — -8.91; -11.24 days — p=0.002
Phase 3 N=36 Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis
Eyelash Hypotrichosis
Primary: Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA) — 88.9; 27.8 Percentage of…
Phase 3 N=671 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival — 9.9; 9.1 Months